These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 36129152)

  • 1. Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review).
    Ma X; Wu J; Wang B; Liu C; Liu L; Sun C
    Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
    Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
    J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review).
    Tang Q; Zhao S; Zhou N; He J; Zu L; Liu T; Song Z; Chen J; Peng L; Xu S
    Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36866750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy targeting PD‑1/PD‑L1: A potential approach for the treatment of cancer bone metastases (Review).
    Hiraga T
    Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38362963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
    Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
    Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).
    You W; Shang B; Sun J; Liu X; Su L; Jiang S
    Oncol Rep; 2020 Aug; 44(2):424-437. PubMed ID: 32627031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
    Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
    Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
    ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
    Amarnath S; Mangus CW; Wang JC; Wei F; He A; Kapoor V; Foley JE; Massey PR; Felizardo TC; Riley JL; Levine BL; June CH; Medin JA; Fowler DH
    Sci Transl Med; 2011 Nov; 3(111):111ra120. PubMed ID: 22133721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
    Li CJ; Lin LT; Hou MF; Chu PY
    Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using phage-assisted continuous evolution (PACE) to evolve human PD1.
    Ye X; Tu M; Piao M; Yang L; Zhou Z; Li Z; Lin M; Yang Z; Zuo Z
    Exp Cell Res; 2020 Nov; 396(1):112244. PubMed ID: 32860814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of PD‑L1 in colorectal cancer (Review).
    Ntomi V; Foukas P; Papaconstantinou D; Antonopoulou I; Pikoulis A; Panagiotides I; Pikoulis E; Syrigos K
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine.
    Albershardt TC; Parsons AJ; Reeves RS; Flynn PA; Campbell DJ; Ter Meulen J; Berglund P
    Vaccine; 2020 Apr; 38(17):3369-3377. PubMed ID: 32088020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.
    Ameli F; Shajareh E; Mokhtari M; Kosari F
    BMC Cancer; 2022 Aug; 22(1):848. PubMed ID: 35922773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.